Overview & mechanism
RC-T is a single peptide that activates two complementary incretin receptors. This dual mechanism has shown greater HbA1c reduction and weight loss compared with single-receptor agonists in head-to-head research, along with improvements in lipid profiles and insulin sensitivity.
Research dose & half-life
- Half-life:
- ~5 days
- Research dose:
- Standard research titration: 2.5 mg weekly x 4 wks, then step up by 2.5 mg every 4 wks as tolerated up to 15 mg weekly, subcutaneous.
Safety & side effects
Same class-effect profile as RC-S, often more pronounced at higher doses: nausea, vomiting, diarrhea, constipation, decreased appetite, and injection-site reactions. Serious: pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia when stacked with insulin/sulfonylureas, and vision changes with rapid glucose drops. Same MTC/MEN2 contraindication as other incretin-class peptides. Avoid in pregnancy. Escalate no faster than every 4 weeks and hold or reduce dose if GI symptoms are severe.